Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands
de Jongh, Felix E., Efe, Reva, Herrmann, Kirsten H., Spoorendonk, Jelle A.
Published in International journal of breast cancer (22.09.2022)
Published in International journal of breast cancer (22.09.2022)
Get full text
Journal Article
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands
Simons, Martijn J H G, Machielsen, Peter M, Spoorendonk, Jelle A, Ignacio, Tim, Drost, Pieter B, Jacobs, Tim, de Jongh, Felix E
Published in Journal of medical economics (2024)
Published in Journal of medical economics (2024)
Get full text
Journal Article
2-Year Real-World Outcomes with Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: Literature Review and Meta-analysis of Patient-Relevant Outcomes
Carrasco, Joao, Daien, Vincent, Eldem, Bora M., Spoorendonk, Jelle A., Yoon, Jisu
Published in Ophthalmology and therapy (01.09.2021)
Published in Ophthalmology and therapy (01.09.2021)
Get full text
Journal Article
A novel nonribose agonist, LUF5834, engages residues that are distinct from those of adenosine-like ligands to activate the adenosine A(2a) receptor
Lane, J Robert, Klein Herenbrink, Carmen, van Westen, Gerard J P, Spoorendonk, Jelle A, Hoffmann, Carsten, IJzerman, Adriaan P
Published in Molecular pharmacology (01.03.2012)
Published in Molecular pharmacology (01.03.2012)
Get full text
Journal Article
A Novel Nonribose Agonist, LUF5834, Engages Residues That Are Distinct from Those of Adenosine-Like Ligands to Activate the Adenosine A 2a Receptor
Lane, J. Robert, Klein Herenbrink, Carmen, van Westen, Gerard J. P., Spoorendonk, Jelle A., Hoffmann, Carsten, IJzerman, Adriaan P.
Published in Molecular pharmacology (01.03.2012)
Published in Molecular pharmacology (01.03.2012)
Get full text
Journal Article